What is Zacks Research’s Estimate for AbbVie Q3 Earnings?

AbbVie Inc. (NYSE:ABBV) – Research analysts at Zacks Research issued their Q3 2025 earnings per share (EPS) estimates for shares of AbbVie in a research report issued on Tuesday, October 21st. Zacks Research analyst Team forecasts that the company will earn $1.78 per share for the quarter. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q4 2025 earnings at $3.33 EPS, FY2025 earnings at $10.54 EPS, Q2 2026 earnings at $3.57 EPS, Q3 2026 earnings at $3.64 EPS, FY2026 earnings at $13.91 EPS, Q1 2027 earnings at $3.18 EPS, Q2 2027 earnings at $3.84 EPS, Q3 2027 earnings at $4.02 EPS and FY2027 earnings at $15.18 EPS.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts’ consensus estimates of $3.24 by ($0.27). The firm had revenue of $15.42 billion for the quarter, compared to analyst estimates of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.65 earnings per share.

ABBV has been the subject of a number of other reports. Daiwa Capital Markets upgraded AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a report on Thursday, August 7th. Evercore ISI upped their price objective on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Morgan Stanley upped their price objective on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Hsbc Global Res downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Finally, Bank of America upped their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $234.80.

AbbVie Trading Down 1.2%

ABBV stock opened at $228.57 on Thursday. The company has a market cap of $403.79 billion, a price-to-earnings ratio of 108.84, a PEG ratio of 1.44 and a beta of 0.51. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The business has a fifty day simple moving average of $219.78 and a 200-day simple moving average of $198.28. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 2.9%. The ex-dividend date is Wednesday, October 15th. AbbVie’s dividend payout ratio is currently 312.38%.

Insider Buying and Selling at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president owned 58,247 shares of the company’s stock, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by corporate insiders.

Institutional Trading of AbbVie

Several large investors have recently modified their holdings of ABBV. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie during the second quarter valued at about $25,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the second quarter valued at about $26,000. TD Capital Management LLC grew its stake in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares in the last quarter. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the second quarter valued at about $28,000. Finally, Abound Financial LLC acquired a new stake in shares of AbbVie during the first quarter valued at about $30,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.